Advertisement

Effects of altering infusion parameters on intimal hyperplasia following local catheter-based delivery into the rabbit iliac artery

      Abstract

      Background: Efficient local gene or drug therapy requires optimized application modalities to avoid vessel damage, which might lead to increased neointimal hyperplasia. Aim of the study was to evaluate different application parameters for local delivery using the channeled balloon catheter in order to minimize vessel trauma induced by local application. Methods and results: Sixty cholesterol fed rabbits were randomly enrolled into twelve groups of different local application parameters: group I, application pressure 2 atm/application volume 1 ml physiologic saline; group II, 2 atm/2 ml; group III, 2 atm/5 ml; group IV, 4 atm/1 ml; group V, 4 atm/2 ml; group VI, 4 atm/5 ml. The other six groups received Ringer’s solution instead of saline. Administration of the solution was randomly performed in one iliac artery using the channeled balloon catheter with simultaneous balloon angioplasty (8 atm). The contralateral iliac artery served as a control and was treated with balloon angioplasty only. Four weeks after local therapy, calibrated angiography was performed; the animals were sacrificed, vessel segments were excised and quantitative morphometric measurements were obtained. In none of the animals acute complications, e.g. dissection, thrombosis or perforation of the vessel, was noted. Up to an application pressure of 4 atm and an application volume of 5 ml, no significant neointima formation was seen compared to arteries which underwent angioplasty only. Additionally, no significant differences between saline and Ringer’s solution were detected. In a multivariate analysis, neither application pressure nor volume were found to have a statistically significant influence on the amount of neointimal hyperplasia. Conclusions: Local application of “drugs” using the channeled balloon catheter is safe and feasible without significant induction of neointimal hyperplasia compared to angioplasty, if an application volume of 5 ml and a pressure of 4 atm is not exceeded.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Krepel V.M.
        • van Andel G.J.
        • van Erp W.F.M.
        Percutaneous transluminal angioplasty of the femoropopliteal artery: initial and long term results.
        Radiology. 1985; 156: 325-328
        • Dormandy J.A.
        • Rutherford R.B.
        Management of peripheral arterial disease (PAD). TASC Working Group. Trans Atlantic Inter-Society Concensus (TASC).
        J. Vasc. Surg. 2000; 31: S1-S296
        • Bauters C.
        • Meurice T.
        • Hamon M.
        • McFadden E.
        • Lablanche J.M.
        • Bertrand M.E.
        Mechanisms and prevention of restenosis: from experimental models to clinical practice.
        Cardiovasc. Res. 1996; 31: 835-846
        • Liu M.W.
        • Roubin G.S.
        • King S.B.I.
        Restenosis after coronary angioplasty: potential biological determinants and role of intimal hyperplasia.
        Circulation. 1989; 79: 1374-1387
        • Popma J.J.
        • Califf R.M.
        • Topol E.J.
        Clinical trials of restenosis after coronary angioplasty.
        Circulation. 1991; 84: 1426-1436
        • Ip J.H.
        • Fuster V.
        • Badimon L.
        • Badimon J.
        • Taubman M.B.
        • Chesebro J.H.
        Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation.
        J. Am. Coll. Cardiol. 1990; 15: 1667-1687
        • Hermans W.R.M.
        • Rensing B.J.
        • Strauss B.H.
        • Serruys P.W.
        Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a ‘magic bullet’.
        Am. Heart J. 1991; 122: 171-187
        • Glagov S.
        Intimal hyperplasia, vascular modeling, and the restenosis problem.
        Circulation. 1994; 89: 2888-2891
      1. MERCATOR study group: does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal angioplasty. J Am Coll Cardiol 1989;13:665–72.

        • Dusting G.J.
        • Hyland R.
        • Hickey H.
        • Makdissi M.
        Angiotensin converting enzyme inhibitors reduce neointimal thickening and maintain endothelial nitric oxide function in rabbit carotid arteries.
        Am. J. Cardiol. 1995; 76: 24E-27E
        • Powell J.S.
        • Glozel J.P.
        • Muller R.K.
        • Kuhn H.
        • Hefti F.
        • Hosang M.
        • et al.
        Inhibitors of ACE prevent myointimal proliferation after vascular injury.
        Science. 1989; 245: 186-188
        • Powell J.S.
        • Muller R.K.M.
        • Baumgartner H.R.
        Suppression of the vascular response to injury: the role of angiotensin-converting enzyme inhibitors.
        J. Am. Coll. Cardiol. 1991; 17: 137B-142B
        • Riessen R.
        • Isner J.M.
        Prospects for site-specific delivery of pharmacologic and molecular therapies.
        J. Am. Coll. Cardiol. 1994; 23: 1234-1244
        • Lincoff A.M.
        • Topol E.J.
        • Ellis S.G.
        Local drug delivery for the preventon of restenosis. Fact, fancy and future.
        Circulation. 1994; 90: 2080-2084
        • Nunes G.L.
        • Thomas C.N.
        • Hanson S.R.
        • Barry J.J.
        • King III, S.B.
        • Scott N.A.
        Inhibition of platelet-dependent thrombosis by local delivery of heparin with a hydrogel coated balloon.
        Circulation. 1995; 92: 1697-1700
        • Gonschior P.
        • Goetz A.E.
        • Huehns T.Y.
        • Hofling B.
        A new catheter for prolonged local drug application.
        Coronary Artery Dis. 1995; 6: 329-334
        • Mitchel J.F.
        • Barry J.J.
        • Bow L.
        • Alberghini T.A.
        • Abbas S.A.
        • McKay R.G.
        Local urokinase delivery with the channel balloon: device safety, pharmacokinetics of intracoronary drug delivery, and efficacy of thrombolysis.
        Catheterizat. Cardiovasc. Diag. 1997; 41: 254-260
        • Mitchel J.F.
        • Azrin M.A.
        • Fram D.B.
        • Bow L.M.
        • McKay R.G.
        Localized delivery of heparin to angioplasty sites with iontophoresis.
        Catheterizat. Cardiovasc. Diag. 1997; 41: 315-323
        • Hong M.K.
        • Wong S.C.
        • Farb A.
        • Mehlman M.D.
        • Virmani R.
        • Barry J.J.
        • et al.
        Feasibility and drug delivery efficiency of a new balloon angioplasty catheter capable of performing simultaneous local drug delivery.
        Coronary Artery Dis. 1993; 4: 1023-1027
        • Camenzind E.
        • Bakker W.H.
        • Reijs A.
        • van Geijlswijk I.M.
        • Boersma E.
        • Kutryk M.J.
        • et al.
        Site specific intracoronary heparin delivery in humans after balloon angioplasty: a radioisotopic assessment of regional pharmacokinetics.
        Circulation. 1997; 96: 154-165
        • Camenzind E.
        • Reijs A.
        • Ligthart J.
        • Krenning E.P.
        • Roelandt J.R.
        • Serruys P.W.
        Local intracoronary delivery of heparin and of a somatostatin analogue (octreotide) following angioplasty in man: evaluation of efficacy of delivery by radioisotopic technique.
        J. Am. Coll. Cardiol. 1995; 25: 285
        • Camenzind E.
        • Schaar M.
        • Bakker W.
        • Reijs A.
        • van Geijlswijk I.M.
        • Boersma E.
        • et al.
        First experience in human: safety and feasibility of local intracoronary heparin delivery using the channelled balloon.
        Eur. Heart J. 1997; 18: 507
        • Moura A.
        • Lam J.Y.
        • Hebert D.
        • Kermode J.R.
        • Grant G.W.
        • Robitaille D.
        • et al.
        Intramural delivery of agent via a novel drug delivery device.
        Circulation. 1995; 92: 2299-2305
        • Chapman G.D.
        • Lim C.S.
        • Gammon R.S.
        • Culp S.C.
        • Desper J.S.
        • Bauman R.P.
        • et al.
        Gene transfer into coronary arteries of intact animals with a percutaneous balloon catheter.
        Circ. Res. 1992; 71: 27-33
        • Perlman H.
        • Maillard L.
        • Krasinski K.
        • Walsh K.
        Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury.
        Circulation. 1997; 95: 981-987
        • Plante G.
        • Dupuis G.
        • Mongeau C.J.
        • Durand P.
        Porous balloon catheters for local delivery: assessment of vascular damage in a rabbit iliac angioplasty model.
        J. Am. Coll. Cardiol. 1994; 24: 820-824
      2. March K, Trapnell BC. Pharmacokinetics of local vector delivery to vascular tissues: implications for efficiency and localization of transduction. In: March KL, editor. Gene transfer in the cardiovascular system. Norwell, MA: Kluwer Academic Publishers. pp. 477–98.

        • Goldman B.
        • Blanke H.
        • Wolinsky H.
        Influence of pressure on permeability of normal and diseased muscular arteries to horseradish peroxidase. A new catheter approach.
        Atherosclerosis. 1987; 65: 215-225
        • Lambert C.R.
        • Leone J.F.
        • Howland S.M.
        Local drug delivery. Functional comparison of porous and microporous designs.
        Coronary Artery Dis. 1993; 5: 469-475
        • Wilensky R.
        • March L.
        • Hathaway D.
        Direct intraarterial wall injection of microparticles via catheter. A possible drug delivery strategy following angioplasty.
        Am. Heart J. 1991; 22: 1131-1140
        • Penn M.S.
        • Saidel G.M.
        • Chisolm G.M.
        Relative significance of endothelium and internal elastic lamina in regulating the entry of macromolecules into arteries in vivo.
        Circ. Res. 1994; 74: 74
        • Wolinsky H.
        • Thung S.N.
        Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery.
        J. Am. Coll. Cardiol. 1990; 15: 475-481
        • Baumbach A.
        • Herdeg C.
        • Kluge M.
        • Oberhoff M.
        • Lerch M.
        • Haase K.K.
        • et al.
        Local drug delivery: impact of pressure, substance characteristics, and stenting on drug transfer into the arterial wall.
        Catheterizat. Cardiovasc. Intervent. 1999; 47: 102-106
        • Alfke H.
        • Wagner H.J.
        • Calmer C.
        • Klose K.J.
        Local intravascular drug delivery: in vitro comparison of three catheter systems.
        Cardiovasc. Intervent. Radiol. 1998; 21: 50-56
        • Muller D.W.M.
        • Ellis S.G.
        • Topol E.J.
        Experimental models of coronary artery restenosis.
        J. Am. Coll. Cardiol. 1992; 19: 418-432
        • Kalinowski M.
        • Alfke H.
        • Bergen S.
        • Klose K.J.
        • Barry J.J.
        • Wagner H.J.
        Comparative trial of local pharmacotherapy with l-arginine, r-hirudin and molsidomine to reduce restenosis after balloon angioplasty of stenotic rabbit iliac arteries.
        Radiology. 2001; 219: 716-723
        • Teirstein P.S.
        • Kuntz R.E.
        New frontiers in interventional cardiology: intravascular radiation to prevent restenosis.
        Circulation. 2001; 104: 2620-2626
        • Sousa J.E.
        • Costa M.A.
        • Abizaid A.C.
        • Rensing B.J.
        • Abizaid A.S.
        • Tanajura L.F.
        • et al.
        Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up.
        Circulation. 2001; 104: 2007-2011
        • Degertekin M.
        • Serruys P.W.
        • Foley D.P.
        • Tanabe K.
        • Regar E.
        • Vos J.
        • et al.
        Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up.
        Circulation. 2002; 24: 1610-1613
        • Kataoka T.
        • Grube E.
        • Honda Y.
        • Morino Y.
        • Hur S.H.
        • Bonneau H.N.
        • et al.
        7-hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE).
        Circulation. 2002; 1: 1788-1793
        • Duda S.H.
        • Pusisch B.
        • Richter G.
        • Landwehr P.
        • Oliva V.L.
        • Tielbeek A.
        • et al.
        Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease. Six-month results.
        Circulation. 2002; 106: 1505-1509